Olean-12-Eno[2,3-c] [1,2,5]Oxadiazol-28-Oic Acid (OEOA) Induces G1 Cell Cycle Arrest and Differentiation in Human Leukemia Cell Lines

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Ng, Yu Pong ^a   Chen, Yuewen ^a,b   Hu, Yueqing ^a   Ip, Fanny C F ^a,b   Ip, Nancy Y ^a,b  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLEAN 12 ENO[2,3 C][1,2,5]OXADIAZOL 28 OIC ACID; OLEANOLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; ERYTHROID CELL; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; NEWBORN; PROTEIN EXPRESSION;

EID: 84877795910     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063580     Document Type: Article

References (51)

1. Burnett A, Wetzler M, Löwenberg B, (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29: 487-494.
2. Ribera JM, (2011) Advances in acute lymphoblastic leukemia in adults. Curr Opin Oncol 23: 692-699.
3. Guilhot F, Roy L, Tomowiak C, (2012) Current treatment strategies in chronic myeloid leukemia. Curr Opin Hematol 19: 102-109.
4. Hsi ED, (2012) Pathologic and molecular genetic features of chronic lymphocytic leukemia. Semin Oncol 39: 74-79.
5. National Cancer Institute (2012) Leukemia http://www.cancer.gov/cancertopics/types/leukemia.Accessed on 6th Sept/. 2012.
6. Pleyer L, Egle A, Hartmann TN, Greil R, (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 6: 405-418.
7. Crazzolara R, Bendall L, (2009) Emerging treatments in acute lymphoblastic leukemia. Curr Cancer Drug Targets 9: 19-31.
8. Jabbour E, Parikh SA, Kantarjian H, Cortes J, (2011) Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 25: 981-995.
9. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, et al. (2012) Drug resistance: Still a daunting challenge to the successful treatment of AML. Drug Resist Updat 15: 62-69.
10. Kowalski R, (2007) Studies of selected plant raw materials as alternative sources of triterpenes of oleanolic and ursolic acid types. J Agric Food Chem 55: 656-662.
11. Jäger S, Trojan H, Kopp T, Laszczyk MN, Scheffler A, (2009) Pentacyclic triterpene distribution in various plants- rich sources for a new group of multi-potent plant extracts. Molecules 14: 2016-2031.
12. Liu J, (2005) Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 100: 92-94.
13. Sultana N, Ata A, (2008) Oleanolic acid and related derivatives as medicinally important compounds. J Enzyme Inhib Med Chem 23: 739-756.
14. Ovesná Z, Vachálková A, Horváthová K, Tóthová D, (2004) Pentacyclic triterpenoic acids: new chemoprotective compounds. Minireview. Neoplasma 51: 327-333.
15. Furtado RA, Rodrigues EP, Araújo FR, Oliveira WL, Furtado MA, et al. (2008) Ursolic acid and oleanolic acid suppress preneoplastic lesions induced by 1,2-dimethylhydrazine in rat colon. Toxicol Pathol 36: 576-580.
16. Laszczyk MN, (2009) Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med 75: 1549-1560.
17. Sogno I, Vannini N, Lorusso G, Cammarota R, Noonan DM, et al. (2009) Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. Recent Results Cancer Res 181: 209-212.
18. Bishayee A, Ahmed S, Brankov N, Perloff M, (2011) Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci 16: 980-996.
19. Lu XM, Yi HW, Xu JL, Sun Y, Li JX, et al. (2007) A novel synthetic oleanolic acid derivative with amino acid conjugate suppresses tumour growth by inducing cell cycle arrest. J Pharm Pharmacol 59: 1087-1093.
20. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, et al. (2010) Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res 70: 4949-4960.
21. Chen J, Liu J, Zhang L, Wu G, Hua W, et al. (2006) Pentacyclic triterpenes. Part 3: Synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase. Bioorg Med Chem Lett 16: 2915-2919.
22. Crissman HA, Steinkamp JA, (1982) Rapid, one step staining procedures for analysis of cellular DNA and protein by single and dual laser flow cytometry. Cytometry 3: 84-90.
23. Cheung WM, Chu AH, Chu PW, Ip NY, (2001) Cloning and expression of a novel nuclear matrix-associated protein that is regulated during the retinoic acid-induced neuronal differentiation. J Biol Chem 276: 17083-17091.
24. Lampronti I, Bianchi N, Borgatti M, Fibach E, Prus E, et al. (2003) Accumulation of gamma-globin mRNA in human erythoid cells treated with angelicin. Eur J Haematol 71: 189-195.
25. Olsson I, Bergh G, Ehinger M, Gullberg U, (1996) Cell differentiation in acute myeloid leukemia. Eur J Haematol 57: 1-16.
26. Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, et al. (2010) Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 9: 689-699.
27. Suryadinata R, Sadowski M, Sarcevic B, (2010) Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci Rep 30: 243-255.
28. Decker T, Schneller F, Hipp S, Miething C, Jahn T, et al. (2002) Cell cycle progression of chonic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 16: 327-334.
29. Nagano K, Itagaki C, Izumi T, Nunomura K, Soda Y, et al. (2006) Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase. Oncogene 25: 493-502.
30. Pan HW, Chou HY, Liu SH, Peng SY, Liu CL, et al. (2006) Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle 5: 2676-2687.
31. Ueki T, Nishidate T, Park JH, Lin ML, Shimo A, et al. (2008) Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene 27: 5672-5683.
32. Li J, Ng EK, Ng YP, Wong CY, Yu J, et al. (2009) Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer. Br J Cancer 101: 691-698.
33. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zöllner H, Munding J, et al. (2012) MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 33: 732-739.
34. Brognara E, Lampronti I, Breveglieri G, Accetta A, Corradini R, et al. (2011) C(5) modified uracil derivatives showing antiproliferative and erythroid differentiation inducing activities on human chronic myelogenous leukemia K562 cells. Eur J Pharmacol 672: 30-37.
35. Rangatia J, Bonnet D, (2006) Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 20: 68-76.
36. Brózik A, Casey NP, Hegedus C, Bors A, Kozma A, et al. (2006) Reduction of Bcr-Abl function leads to erythoid differentiation of K562 cells via downregulation of ERK. Ann N Y Acad Sci 1090: 344-354.
37. Fukuchi Y, Yamato K, Kawamura C, Ikeda Y, Kizaki M, (2006) p27KIP1 and GATA-1 are potential downstream molecules in activin A-induced differentiation and apoptosis pathways in CML cells. Oncol Rep 16: 1099-1103.
38. Moosavi MA, Yazdanparast R, Lotfi A, (2007) ERK1/2 inactivation and p38 MAPK-dependent caspase activation during guanosine 5′-triphosphate-mediated terminal erythoid differentiation of K562 cells. Int J Biochem Cell Biol 39: 1685-1697.
39. Acosta JC, Ferrándiz N, Bretones G, Torrano V, Blanco R, et al. (2008) Myc inhibits p27-induced erythoid differentiation of leukemia cells by repressing erythoid master genes without reversing p27-mediated cell cycle arrest. Mol Cell Biol 28: 7286-7295.
40. Li N, Liu C, Mi S, Wang N, Zheng X, et al. (2012) Simultaneous determination of oleanolic acid, p-coumaric acid, ferulic acid, kaemperol and quercetin in rat plasma by LC-MS-MS and application to a pharmacokinetic study of Oldenlandia diffusa extract in rats. J Chromatogr Sci 50: 885-892.
41. Konopleva M, (2010) Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res 70: 4949-4960.
42. Koschmieder S, D'Alò F, Radomska H, Schöneich C, Chang JS, et al. (2007) CDDO induces granulocytic differentiation of myeloid leukemic blasts though translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood 110: 3695-3705.
43. Lee J, Kim SS, (2009) The function of p27 KIP1 during tumor development. Exp Mol Med 41: 765-771.
44. Perrotti D, Jamieson C, Goldman J, Skorski T, (2010) Chonic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 120: 2254-2264.
45. Naka K, Hoshii T, Hirao A, (2010) Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chonic myeloid leukemia stem cells. Cancer Sci 101: 1577-1581.
46. Bixby D, Talpaz M, (2011) Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25: 7-22.
47. Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP, (2003) Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ 10: 592-598.
48. Cao T, Heng BC, (2005) Differentiation therapy of cancer. Potential advantages over conventional therapeutic approaches targeting death of cancer/tumor cells. Med Hypotheses 65: 1202-1203.
49. Sell S, (2005) Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev 1: 197-205.
50. Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, et al. (2012) p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol 39: 97-108.
51. Landi M, Catelani G, D'Andrea F, Ghidini E, Amari G, et al. (2009) Synthesis of glycose carbamides and evaluation of the induction of erythoid differentiation of human erytholeukemic K562 cells. Eur J Med Chem 44: 745-754.